The Adrenomyeloneuropathy (AMN) drugs in development market research report provides comprehensive information on the therapeutics under development for Adrenomyeloneuropathy (AMN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Adrenomyeloneuropathy (AMN). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Adrenomyeloneuropathy (AMN) and features dormant and discontinued products.
GlobalData tracks six drugs in development for Adrenomyeloneuropathy (AMN) by four companies/universities/institutes. The top development phase for Adrenomyeloneuropathy (AMN) is phase i with three drugs in that stage. The Adrenomyeloneuropathy (AMN) pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Adrenomyeloneuropathy (AMN) pipeline products market are: Poxel, Viking Therapeutics and SwanBio Therapeutics.
The key targets in the Adrenomyeloneuropathy (AMN) pipeline products market include Mitochondrial Pyruvate Carrier, Thyroid Hormone Receptor Beta, and Adenosine Monophosphate Activated Protein Kinase.
The key mechanisms of action in the Adrenomyeloneuropathy (AMN) pipeline product include Thyroid Hormone Receptor Beta Agonist with two drugs in Phase I. The Adrenomyeloneuropathy (AMN) pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Adrenomyeloneuropathy (AMN) pipeline products market including Small Molecule, and Gene Therapy.
Adrenomyeloneuropathy (AMN) overview
Adrenomyeloneuropathy (AMN) is an inherited condition that affects the spinal cord. It is a form of X-linked adrenoleukodystrophy. On average, people with AMN begin to develop features in the late twenties. Signs and symptoms may include progressive stiffness and weakness of the legs; ataxia; speech difficulties; adrenal insufficiency; sexual dysfunction; and bladder control issues
For a complete picture of Adrenomyeloneuropathy (AMN)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
